{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T10:35:01Z","timestamp":1722767701264},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00280-017-3482-7","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T08:32:24Z","timestamp":1511253144000},"page":"163-169","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors"],"prefix":"10.1007","volume":"81","author":[{"given":"Lingaku","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhide","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"3482_CR1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734\u2013745","journal-title":"Nat Rev Drug Discov"},{"key":"3482_CR2","first-page":"1469","volume":"9","author":"MH Fj\u00e4llskog","year":"2003","unstructured":"Fj\u00e4llskog MH, Lejonklou MH, \u00d6berg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469\u20131473","journal-title":"Clin Cancer Res"},{"key":"3482_CR3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"key":"3482_CR4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, H\u00f6rsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501\u2013513","journal-title":"N Engl J Med"},{"key":"3482_CR5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10637-012-9910-y","volume":"31","author":"T Ito","year":"2013","unstructured":"Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M (2013) Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31:1265\u20131274","journal-title":"Invest New Drugs"},{"issue":"3","key":"3482_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3367-9","volume":"80","author":"Y Wang","year":"2017","unstructured":"Wang Y, Jin K, Tan H, Zhang P, Yang Q, Wang W, Li J, Shao C, Xue L, Feng S, Chen M, Yu X, Chen J (2017) Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol 80(3):507\u2013516","journal-title":"Cancer Chemother Pharmacol"},{"key":"3482_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-016-3215-3","volume":"79","author":"C Yoo","year":"2017","unstructured":"Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY (2017) Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol 79:139\u2013146","journal-title":"Cancer Chemother Pharmacol"},{"key":"3482_CR8","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"3482_CR9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371\u20131377","journal-title":"J Clin Oncol"},{"key":"3482_CR10","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, DePrimo SE, Harmon CS, Law CNJ, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959\u20131968","journal-title":"Eur J Cancer"},{"key":"3482_CR11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329\u20131338","journal-title":"Lancet"},{"key":"3482_CR12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/0284186X.2016.1265666","volume":"56","author":"X Liu","year":"2017","unstructured":"Liu X, Fiocco M, Swen JJ, Guchelaar HJ (2017) Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. Acta Oncol 56:582\u2013589","journal-title":"Acta Oncol"},{"key":"3482_CR13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI (2014) A 2\u00a0weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 50:1084\u20131089","journal-title":"Eur J Cancer"},{"key":"3482_CR14","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, Ahn JH, Lee DH, Ryoo HM, Song C, Hong B, Hong JH, Ahn H (2015) RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol 26:2300\u20132305","journal-title":"Ann Oncol"},{"key":"3482_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jjco\/hyt232","volume":"44","author":"T Kondo","year":"2014","unstructured":"Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K (2014) Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma\u2013comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol 44:270\u2013277","journal-title":"Jpn J Clin Oncol"},{"key":"3482_CR16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11523-014-0349-2","volume":"10","author":"YL Teo","year":"2015","unstructured":"Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2015) Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted Oncol 10:429\u2013437","journal-title":"Targeted Oncol"},{"key":"3482_CR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1248\/bpb.b14-00636","volume":"38","author":"M Nagata","year":"2015","unstructured":"Nagata M, Ishiwata Y, Takahashi Y, Takahashi H, Saito K, Fujii Y, Kihara K, Yasuhara M (2015) Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. Biol Pharm Bull 38:402\u2013410","journal-title":"Biol Pharm Bull"},{"key":"3482_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/theoncologist.2016-0175","volume":"22","author":"M Ter-Minassian","year":"2017","unstructured":"Ter-Minassian M, Zhang S, Brooks NV, Brais LK, Chan JA, Christiani DC, Lin X, Gabriel S, Dinet J, Kulke MH (2017) Association between tumor progression endpoints and overall survival in patients with advanced neuroendocrine tumors. Oncologist 22:165\u2013172","journal-title":"Oncologist"},{"key":"3482_CR19","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system (IARC WHO Classification of Tumours), 4th\u00a0edn. IARC press, Lyon, pp\u00a0322\u2013326"},{"key":"3482_CR20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","volume":"50","author":"T Ito","year":"2015","unstructured":"Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, Takayanagi R, Shimatsu A (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58\u201364","journal-title":"J Gastroenterol"},{"key":"3482_CR21","first-page":"1131","volume":"45","author":"L Lee","year":"2015","unstructured":"Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T (2015) Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: A single-center retrospective study. Jpn J Clin Oncol 45:1131\u20131138","journal-title":"Jpn J Clin Oncol"},{"key":"3482_CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jhbp.418","volume":"24","author":"L Lee","year":"2017","unstructured":"Lee L, Ito T, Igarashi H, Ueda K, Fujiyama T, Kawabe K, Ogawa Y (2017) Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. J Hepato-Biliary-Pancreat Sci 24:95\u2013102","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"issue":"Suppl 4","key":"3482_CR23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2017.35.4_suppl.380","volume":"35","author":"E Raymond","year":"2017","unstructured":"Raymond E, Kulke MH, Qin S, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu J, Racz DK, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Fernandez KC, Rosbrook B, Fazio N (2017) The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. J Clin Oncol 35(Suppl 4):380","journal-title":"J Clin Oncol"},{"key":"3482_CR24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","volume":"101","author":"S Novello","year":"2009","unstructured":"Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101:1543\u20131548","journal-title":"Br J Cancer"},{"key":"3482_CR25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","volume":"40","author":"Y Tomita","year":"2010","unstructured":"Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166\u20131172","journal-title":"Jpn J Clin Oncol"},{"key":"3482_CR26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10637-009-9306-9","volume":"28","author":"K Shirao","year":"2010","unstructured":"Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A (2010) Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28:866\u2013875","journal-title":"Invest New Drugs"},{"key":"3482_CR27","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","volume":"15","author":"BE Houk","year":"2009","unstructured":"Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497\u20132506","journal-title":"Clin Cancer Res"},{"key":"3482_CR28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000330361","volume":"80","author":"HS Kim","year":"2011","unstructured":"Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY (2011) Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology (Switz) 80:395\u2013405","journal-title":"Oncology (Switz)"},{"key":"3482_CR29","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ctrv.2014.09.001","volume":"40","author":"JW Valle","year":"2014","unstructured":"Valle JW, Faivre S, Hubner RA, Grande E, Raymond E (2014) Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 40:1230\u20131238","journal-title":"Cancer Treat Rev"},{"key":"3482_CR30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","volume":"45","author":"H Akaza","year":"2015","unstructured":"Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Lowenthal SP, Lee SY (2015) Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol 45:576\u2013583","journal-title":"Jpn J Clin Oncol"},{"key":"3482_CR31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357\u2013371","journal-title":"Cancer Chemother Pharmacol"},{"key":"3482_CR32","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1007\/s12032-012-0236-6","volume":"29","author":"A Kawashima","year":"2012","unstructured":"Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, Nishimura K, Nonomura N (2012) Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Med Oncol 29:3298\u20133305","journal-title":"Med Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3482-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T02:34:31Z","timestamp":1515033271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3482-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3482"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3482-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}